Transvaginal Ultrasound and Photoacoustic Imaging of the Ovary

Washington University School of Medicine40 enrolled

Overview

The investigators have developed co-registered photoacoustic and ultrasound (US) imaging technique that allows the investigators to visualize tumor structure and functional changes simultaneously, which may potentially reveal early tumor angiogenesis development that is not available by US alone. The ability to detect early angiogenesis changes, as well as tumor morphology changes in the ovary, using a non-invasive imaging modality will greatly enhance the care for women.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Oophorectomy

Interventions

Transvaginal ultrasoundDEVICE

-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson

Ultrasound/Photoacoustic imagingDEVICE

-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older * Referred to Washington University School of Medicine for conditions necessitating surgery to include at least a unilateral oophorectomy * Willingness to participate in the study * Able to provide informed consent Exclusion Criteria * Younger than 18 years of age * Not able to provide informed consent

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Measure PAI/ultrasound signatures from ovaries prior to surgery

-The transvaginal US will be performed by US technologists or radiologists at the Radiology Department and images will be read by one of the study radiologists either Dr. Cary Siegel or Dr. Kathryn Robinson of the Radiology Department. The reading will be categorized as normal, suspicious or highly suspicious. The scores will serve as a baseline comparison of US/PAI technique with the current clinical practice using US. Immediately after the transvaginal US, US/PAI imaging will be performed with the assistance of the US technologist or radiologist.

Time frame: Prior to surgery (no more than 30 days prior to surgery)

Secondary Outcomes

Characterize the tissue images with pathologic diagnosis

-The in vivo and ex vivo PAI/US images with be compared with final pathologic diagnosis.

Time frame: At the time of surgery (no more than 30 days after PAI/US)

Refine the system and imaging algorithms based on the characteristic features of in vivo imaging

-Will be used to distinguish between benign and malignant ovarian tissues. Student t-test will be used for statistical significant test of each feature obtained from malignant and benign ovaries. Those features with p value less than 0.05 will be used as a predictor.

Time frame: At the time of surgery (no more than 30 days after PAI/US)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.